TY - JOUR
T1 - Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin
AU - Columbo, Michele
AU - Galeone, Daniela
AU - Guidi, Guido
AU - Kagey-Sobotka, Anne
AU - Lichtenstein, Lawrence M.
AU - Pettit, George
AU - Marone, Gianni
N1 - Funding Information:
* Supported in part by Grants from the C.N.R. ~86.00088.04 and 88.00559.04). the N.I.H. (AI 07290). h.P.I., and “Minister0 SanitB:“(Rome, Italy): The AS61 CR1 component received financial support from the Fannie E. Rippel Foundation, The Arizona Disease Control Research Commission,.the Robert B. Dalton Endowment Fund, and PHS Grants CA-16049-07-12 awarded by the N.C.I., DHHS. )I Correspondence to: Gianni Marone, M.D., University of Naples, II School of Medicine, Department of Medicine, Via S. Pansini 5, 80131 Naples, Italy. f Abbreviations: F-met-peptide, N-formyl-methionyl-leucyl-phenylalanine; HSA, human serum albumin; LTB4, leukotriene B,; LTC,, sulfidopeptide leukotriene C,; LTDI, sulfidopeptide leukotrieneD1; LTE*, sulfidopeptide leukotriene E,: PA. PIPES buffer (DH 7.4) containing human serum’ albumin; PIPES, pi$erazine:N.N’-bis(2: ethanesulfonic acid); TPA. 12-tetradecanoyloxy-13-acetoxy-phorbol.
PY - 1990/1/15
Y1 - 1990/1/15
N2 - Auranofln, a new orally absorbable gold compound, inhibits IgE-(anti-IgE) and non-IgE-mediated (f-met-peptide and the Ca2+ ionophore A23187) histamine release from human basophils. Auranofin inhibits the release of histamine induced by phorbol myristate (TPA) and bryostatin 1 both in the presence and absence of extracellular Ca2+. Increasing the Ca2+ concentrations in the extracellular medium does not reduce the inhibitory effect of auranofin on anti-IgE- or A23187-induced secretion. Auranofin inhibits the de novo synthesis of sulfidopeptide leukotriene C4 (LTC4) induced by anti-IgE from basophils and mast cells purified from human lung. However, in both systems auranofin has a significantly greater inhibitory effect on LTC4 release than on histamine secretion. Finally, auranofin induces a concentration-dependent inhibition of A23187-induced leukotrine B4 (LTB4) release from purified human lung macrophages. These data suggest that auranofin modulates the release of preformed (histamine) and de novo synthesized (LTC4 and LTB4) chemical mediators from human inflammatory cells isolated from peripheral blood and human lung tissues.
AB - Auranofln, a new orally absorbable gold compound, inhibits IgE-(anti-IgE) and non-IgE-mediated (f-met-peptide and the Ca2+ ionophore A23187) histamine release from human basophils. Auranofin inhibits the release of histamine induced by phorbol myristate (TPA) and bryostatin 1 both in the presence and absence of extracellular Ca2+. Increasing the Ca2+ concentrations in the extracellular medium does not reduce the inhibitory effect of auranofin on anti-IgE- or A23187-induced secretion. Auranofin inhibits the de novo synthesis of sulfidopeptide leukotriene C4 (LTC4) induced by anti-IgE from basophils and mast cells purified from human lung. However, in both systems auranofin has a significantly greater inhibitory effect on LTC4 release than on histamine secretion. Finally, auranofin induces a concentration-dependent inhibition of A23187-induced leukotrine B4 (LTB4) release from purified human lung macrophages. These data suggest that auranofin modulates the release of preformed (histamine) and de novo synthesized (LTC4 and LTB4) chemical mediators from human inflammatory cells isolated from peripheral blood and human lung tissues.
UR - http://www.scopus.com/inward/record.url?scp=0025052105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025052105&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(90)90027-I
DO - 10.1016/0006-2952(90)90027-I
M3 - Article
C2 - 2105731
AN - SCOPUS:0025052105
SN - 0006-2952
VL - 39
SP - 285
EP - 291
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 2
ER -